Real-world efficacy and tolerability of axitinib + pembrolizumab in the treatment of renal cell carcinoma.
Combination therapy with immune checkpoint inhibitors (ICIs) and vascular endothelial growth factor tyrosine kinase inhibitors (VEGF TKIs) is standard of care for metastatic renal cell carcinoma (mRCC); however, no head-to-head trials have compared FDA- …